

TO THE NATIONAL SECURITIES MARKET COMMISSION

For the purposes of Article 227 of Law 6/2023, of March 17, on Securities Markets and Investment Services, and related provisions, Faes Farma, S.A. hereby informs the market of the following

OTHER RELEVANT INFORMATION

A) BOARD OF DIRECTORS AGREEMENTS

At the General Shareholders' Meeting of the Company validly held today on second call, all the proposals of the Board of Directors included in the different items of the Agenda were approved, among which we highlight the following:

- **Approval of the corporate management, the financial statements and management report, both of the Company and of its consolidated Group, and of the proposed allocation of the profit for the year 2024, as well as the Consolidated Statement of Non-Financial Information (EINF and Sustainability Information) for 2024.**
- **Approval of the appointment of Ms. Beatriz Faro Morales as independent board member, replacing Mr. Carlos Alcocer Torra, who has completed 12 years as independent board member.**
- **Consultative vote on the Annual Report on Directors' Remuneration for fiscal year 2024.**
- **Approval of the long-term incentive plan through the delivery of Company shares for certain executives and key personnel, including the chief executive officer.**
- **Approval of the Directors' Remuneration Policy for fiscal years 2026, 2027 and 2028, which maintains the improvements of the policy approved the previous year with broad support, incorporating changes derived from the Incentive Plan mentioned in the previous point and in the remuneration of the commissions.**

- **Approval of the authorization to the Board of Directors for the acquisition of treasury stock.**
- **Approval of the appointment of PriceWaterhouseCoopers Auditores, S.L., as auditor of the accounts of the Company and its consolidated group, for the 2026 fiscal year.**
- **Approval of the delegation to the Board of Directors to execute the resolutions adopted at this Meeting.**

B) HIGHLIGHTS

The main points discussed at the General Shareholders' Meeting held today are listed below.

BOARD HIGHLIGHTS

1. All the proposals on the Meeting Agenda were approved.
2. In addition to the Agenda, the Chairman highlighted the following topics, which we briefly summarize:
 - a) With the appointment of Ms. Beatriz Faro Morales as independent board member and the departure of Mr. Carlos de Alcocer Torra, the Board is composed of 10 members, 50% women, thus achieving parity on the Board, and 50% independent directors. It should also be noted that both the Audit and Compliance Committee and the Appointments and Remuneration Committee are composed entirely of independent board directors.
 - b) In terms of sustainability, we will reach 100% renewable electricity in Spain and Guatemala by 2024. In addition, the group is working on a Transition Plan to mitigate climate change. On the social front, 54% of employees are women and we expect to improve diversity by implementing development programs. In the long term, the company seeks to improve ESG performance and raise its sustainability rating in the S&P CSA questionnaire.
 - c) Very positive performance of the share both in 2024, which grew by 10%, and in 2025 with a current growth of 30%, above the Ibex. The company's capitalization as of yesterday exceeds 1.4 billion euros.
 - d) Shareholder remuneration: 0.041 euros cash dividend in January 2025 and 0.138 euros cash dividend to be paid on July 7, 2025 (last day on which shares with dividend rights are traded, July 2), totalling 0.179 euros per share, representing a payout of close to 51% of net income for 2024.
3. For his part, the chief executive officer highlighted the following topics during his speech:
 - a) In this new stage, the corporate culture has been redefined based on a common purpose and values that govern our behaviour, the way we relate to each other and the way we make decisions.
 - b) The company has reinforced its management structure in order to build a more agile, integrated and strategic organization. New key positions and transversal positions have been created, especially oriented towards international growth and

strengthening the Group's key corporate functions.

- c) In April of this year, the new 2025-2030 strategic plan was presented, with which Faes Farma seeks to be recognized as the best global Spanish pharmaceutical company and as a benchmark in the sector. The plan is structured on four pillars: organic growth through a strengthened portfolio, licensing agreements and M&A transactions; investment in R&D&I as a driver of sustainable growth in the medium and long term; commercial and operational excellence to increase production capacity and efficiency; and a strengthened culture, organization and sustainability to generate a positive impact on all stakeholders.
- d) The quantitative ambition of the new strategic plan is to double revenues and EBITDA by 2030 based on the good organic performance of the pharmaceutical business, where international markets will be one of the main drivers and supported by M&A transactions as a strategic expansion lever.
- e) Faes Farma will continue to drive the new era of R&D&I as a driver of sustainable growth with a commitment to allocate 10% of net sales to this area by 2030, up from 6% in 2024, and focused on four high-value therapeutic areas: allergies, bone health, gastrointestinal and ophthalmology.
- f) Another strategic lever is to achieve commercial and operational excellence. The former through market and relationship models with our most advanced customers that allow us to increase commercial efficiency and supported by advanced internal and external data analysis projects and an AI Master Plan that allows us to improve effectiveness. And operational excellence thanks to our new pharmaceutical plant in Derio, which provides the necessary industrial support to accompany the new objectives and with a potential for future expansion that will allow us to absorb long-term growth.
- g) And as the last strategic pillar: to promote a positive impact, with a commitment to sustainability through ethical and responsible practices with a focus on our key stakeholders. Fostering a culture of collective growth and success and generating shareholder value.
- h) During the first half of 2025, two acquisitions have been announced that reinforce

the commitment to the new strategic plan, both in terms of accelerating growth and leading from science: Laboratorio Edol in Portugal and SIFI in Italy (in phase of compliance with suspensive conditions set in SPA), both in line with the profile of target companies that had been defined, framed in a therapeutic area, ophthalmology, with high growth and synergies, with innovative products, in stable and international markets and under the debt/EBITDA ratios set.

Ophthalmology therefore becomes a key therapeutic area for Faes Farma due to the high prevalence and social trends that increase the incidence and also allows us to leverage the strengths of the Group as it fits with our R&D model and our business model.

The first of the operations, Laboratorio Edol, with a total investment of 75 million euros, closed this month, brings a portfolio with incremental innovation capacity, high internationalization potential and solid growth results that will strengthen the Group's overall performance thanks to commercial synergies and cross-selling.

The acquisition of SIFI, also an Italian ophthalmology company, is a transaction that we announced on June 10, which represents a transformational step towards our 2030 strategy and ambition. With an enterprise value of €270 million for an acquisition perimeter that includes a consolidated product business, an emerging ophthalmic CMO business unit and a strategic opportunity for a product targeting an ultra-rare disease. This acquisition reinforces our presence in key markets, in addition to the acquisition of Edol for its complementary product portfolio, and presents synergies between R&D capabilities. It also brings shareholder value by boosting profitability, maintaining dividends and respecting financial discipline criteria.

The closing of this transaction, scheduled for the third quarter of 2025, is subject to a competitive review and approval at an Extraordinary Shareholders' Meeting to be held on July 16.

i) 2024 results review

- 2024 was a record year for results. Revenues of 510 million euros, almost 129 million euros in EBITDA and a net profit of 111.4 million euros, which includes tax deductions derived from the investment in the new Derio plant, were achieved. Without this effect, adjusted profit would have been 94.6 million euros.
Since net income was helped by this one-time impact in 2024, the dividend per share was approximately 18% higher than it would have been without this effect.

- Growth was supported by the good performance of the pharmaceutical sector in Spain, both in medical visits and healthcare, and in international markets, where the good performance of LATAM stood out with 12% growth. The licensing area grew significantly in other licenses, especially due to the new launches of calcifediol, and revenues from bilastin were maintained, absorbing the effect of the entry of generics in some countries and the drop in price in Japan.
- j) Finally, it should be noted that the Derio Plant was approved in December 2024 by the Spanish Agency for Medicines and Health Products and that the new factory in Huesca to produce piglet feed as part of the vertical integration and expansion of the production capacity of the Farm Faes area, began production in the last quarter of 2024.

June 25th, 2025